What Human Metabolome Technologies does

Human Metabolome Technologies, Inc. (HMT) is a Japan-based biotechnology and metabolomics contract research company founded on July 1, 2003, by Professor Tomoyoshi Soga (developer of the CE-MS method at Keio University in 2002) and Professor Masaru Tomita, Director of Keio's Institute for Advanced Biosciences. The company is headquartered at 246-2 Mizukami Kakuganji, Tsuruoka, Yamagata, Japan, with sales operations in Tokyo (Chuo-ku) and a US subsidiary (Human Metabolome Technologies America, Inc.) in Boston, MA. HMT is listed on the Tokyo Stock Exchange (ticker: 6090) with 51–100 employees.

HMT's core technology platform is Capillary Electrophoresis Mass Spectrometry (CE-MS), developed jointly with Keio University and Agilent Technologies, with LC-MS and MS/MS platforms supplementing for lipophilic and broader-coverage metabolite analysis. The service catalog spans OMEGA Scan (untargeted polar metabolomics, 1.5–2x more metabolites vs. basic scan), LC-OMEGA Scan (untargeted lipidomics), Mediator Scan (400 lipid mediators), C-SCOPE (targeted quantitative glycolytic panel of 116 metabolites with three-point calibration), F-SCOPE (isotope flux analysis for C13/N15 tracing), D/L amino acid isomer analysis, and a patented peptidomics approach covering 1,000–10,000 mass range. The full platform measures more than 1,700 metabolites as of November 2025. Reports include PCA, HCA heat maps, pathway mapping, and expert biochemist interpretation, with standard turnaround of 4–8 weeks.

HMT operates a professional-services / CRO business model with quote-based, pay-as-you-go pricing that varies by analysis plan, sample count, and optional add-ons. The company serves pharmaceutical and biotechnology companies (drug discovery, biomarker, preclinical/clinical research), academic and medical research institutions (infectious disease, oncology, neuroscience, regenerative medicine), food and functional ingredient manufacturers (health-claim support, fermentation optimization), chemical/industrial biotech companies (metabolic flux analysis), and government/public-health research organizations. Distribution is hybrid: direct sales in Japan and North America, plus authorized distributors LKLS Co., Ltd. in Korea and GenDiscovery Biotechnology in Taiwan. Marketing is centered on recurring webinars, the Metabolite of the Week educational series, active participation in Japanese scientific conferences (BioJapan, Japanese Society for Bioscience/Biotechnology/Agricultural Chemistry, etc.), and direct inquiry handling through the website and account managers. Complementary revenue streams include biomarker discovery, healthcare solution packages (functional ingredient development, health claim prediction), analysis kits and consumables (centrifugal filters, miRNA panels), and strategic partnerships with MiRXES (miRNA), AutoPhagyGO (autophagy), and AIREX.

Name

Human Metabolome Technologies

Legal name

Human Metabolome Technologies, Inc.

Website

https://humanmetabolome.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Human Metabolome Technologies is a Japan-based contract research organization that provides CE-MS and LC-MS-based metabolomics profiling and biomarker discovery services to pharmaceutical, academic, food/functional-ingredient, and government research customers across Asia-Pacific, North America, and Europe.

Ownership category

akta.pro rank

Product category

Metabolomics Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Metabolomics & Lipidomics Services (HLAGANAG)

akta.pro secondary industries

Proteomics & Mass Spectrometry Services (HLAGANAB), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Metabolomics services
• Mass spectrometry analysis
• Biomarker discovery
• CE-MS platforms
• Metabolome profiling

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Metabolome Analysis Services: HMT's primary revenue stream, offering commissioned metabolomics analysis services across multiple platforms (CE-MS, LC-MS, MS/MS). Services include various analysis plans such as Basic Scan, Advanced Scan, ω Scan, C-SCOPE, F-SCOPE, Dual Scan, Mediator Scan, and optional add-ons. Pricing is quote-based and varies by plan, sample count, and optional analyses. Reports are delivered in PDF with Excel numerical data within 4–8 weeks typically.
2. Biomarker Discovery: HMT conducts research and development of biomarkers related to mental illness and lifestyle diseases, contributing to preventive and personalized medicine. This includes support for cohort study-based biomarker searches, collaborating with academic and clinical partners.
3. Healthcare Solution Services: HMT provides comprehensive support services for functional ingredient development, including biomarker exploration packages, promotion data packages, health claim prediction packages, and fermentation upcycling material development support. Also includes proteome analysis, human skin gas measurement, autophagy activity evaluation, miRNA analysis, and exosome-related analysis services.
4. Analysis Kit and Consumables Sales: HMT sells centrifugal filtration filters and miRNA analysis panels/primers as consumable products alongside its service offerings.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Human Metabolome Technologies (HMT) provides commissioned metabolome analysis services using proprietary Capillary Electrophoresis Mass Spectrometry (CE-MS) and Liquid Chromatography Mass Spectrometry (LC-MS) platforms. The company offers targeted and untargeted metabolomics profiling across more than 1,700 metabolites from biological samples including biofluids, tissues, cells, food, and microbial samples, serving pharmaceutical, academic, food science, and clinical research customers.

Product overview

Human Metabolome Technologies (HMT) offers a comprehensive metabolomics service platform based on capillary electrophoresis mass spectrometry (CE-MS) and liquid chromatography mass spectrometry (LC-MS) technologies. The core offerings include OMEGA Scan for untargeted polar metabolite analysis, Basic/Advanced Scan for hydrophilic profiling, C-SCOPE for quantitative glycolytic panel analysis, Mediator Scan for 400 lipid mediator targets, Dual Scan for combined polar/lipophilic analysis, F-SCOPE for isotope flux analysis, and LC-OMEGA for lipid analysis. Supporting services include biomarker discovery, peptidomics, amino acid analysis, D/L amino acid isomers, tryptophan metabolism panels, sample quality analysis, and flux analysis. HMT also provides specialized services including cohort study packs, proteome analysis, skin gas measurement, autophagy assessment, miRNA analysis (via MiRXES partnership), exosome analysis, and functional ingredient development support with health claim prediction. The platform covers applications in infectious disease, cancer metabolism, microbiome, metabolic diseases, neuroscience, regenerative medicine, and food metabolomics.

Differentiator

Problem solved

Functional benefit

Products and services

• OMEGA Scan HMT's signature untargeted metabolomics platform based on CE-MS, optimized for high-sensitivity analysis of polar, semi-volatile, hydrophilic, and charged metabolites from any biological source. Detects 1.5 to 2 times more metabolites than standard Basic Scan.
• Basic Scan Multi-purpose CE-MS profiling service for a wide range of hydrophilic metabolites, including energy metabolism intermediates, for general screening applications.
• Advanced Scan Comprehensive CE-MS analysis including unknown metabolites for extended-range hydrophilic metabolite profiling with identification capabilities.
• C-SCOPE Targeted Glycolytic Panel Targeted quantitative panel of 116 metabolites in the glycolytic pathway, pentose phosphate pathway, TCA cycle, amino acids, and urea cycle using three-point calibration for absolute quantification. Used for cancer, Warburg effect, and mitochondrial metabolism research.
• Q110 and Q353 Quantitative Polar Panels Targeted panels of 110 or 353 polar metabolites respectively, representing a wide range of metabolite classes. Used with untargeted metabolomics such as OMEGA Scan for comprehensive profiling.
• Mediator Scan (MSCAN) Targeted panel covering 400 bioactive lipids including oxylipins, omega fatty acids, inflammatory lipids (HETEs), EPA, DHA, corticosteroids, lysophospholipids, and middle to very long chain acyl carnitines. Used for inflammation and immune response studies.
• Dual Scan Low-cost option profiling both polar and lipophilic metabolites using Agilent CE-TOFMS system. Identifies more than 1,300 metabolites covering over 1,000 hydrophilic/ionic and 300 lipophilic metabolites. Ideal for plant extracts, agricultural products, and fermentation broths.
• LC-OMEGA Scan Untargeted lipid metabolite analysis using HPLC-MS methods focusing on lipophilic metabolites with high-resolution chromatography and high-resolution high-sensitivity FTMS.
• F-SCOPE Targeted Flux Panel Targets 54 polar metabolites in the glycolytic pathway, TCA cycle, purines and pyrimidines, urea cycle and amino acids to measure C13 and N15 heavy atom labeled metabolite transformations for metabolic flux analysis. Used for in-vivo measurements of glucose oxidation and glutamine metabolism.
• Peptidomics Patented peptidomics approach offering a small peptide library (100 to 1,000 mass) with OMEGA Scan advanced option for bioactive 2-mers to 5-mers, and a patented approach covering 1,000 to 10,000 mass mid-molecular weight range not accessible by standard metabolomics.
• D/L Amino Acids Panel Unique targeted panel of 25 D and L amino acids using derivatization with an optical-center ligand that separates and identifies D and L isomers not resolvable in typical metabolomic chromatography.
• Tryptophan Metabolism Pathway Panel Targeted platform of the tryptophan pathway for inflammation, immune system and neurological condition research.
• Amino Acid Analysis Measures all 20 common amino acids including citrulline and ornithine for biological function analysis including antioxidant activity and ATP synthesis.
• Sample Quality Analysis Data assessment evaluating sample stability using known markers for thermal degradation, hemolysis, platelet contamination and long-term storage to survey biofluids and tissues prior to statistical analysis.
• Fit-4 Purpose Assays Full-service quantitative assays using various forms of capillary electrophoresis and liquid chromatography mass spectrometry, with options validated for research or clinical use.
• Flux Analysis Metabolic flux determination using isotopically labeled substrates to trace metabolites and elucidate active metabolic pathways.
• Biomarker Discovery Metabolomic profiling service supporting biomarker discovery for disease detection, diagnostic markers, and predictive markers in clinical studies.
• Cohort Study Pack Comprehensive support service for cohort studies including metabolomics analysis and biomarker discovery for population health research, incorporating large-scale data correction methodology.
• Metabololo-Index (メタボロインデックス) Biomarker index service using metabolomic data and machine learning algorithms for health assessment and disease prediction.
• Proteome Analysis Proteomics analysis service complementing metabolome analysis for comprehensive molecular profiling.
• Human Skin Gas Measurement Specialized analysis service for measuring volatile metabolites from human skin for non-invasive metabolic profiling.
• Autophagy Activity Assessment Service for evaluating autophagy activity through metabolomic analysis, supporting research in cellular degradation and renewal processes.
• miRNA Analysis (MiRXES ID3EAL) miRNA analysis service using ID3EAL technology through partnership with MiRXES for gene expression analysis.
• Exosome-Related Analysis Analysis service for exosome samples supporting extracellular vesicle research and biomarker discovery.
• Functional Ingredient Development Support Service Comprehensive support package including functional ingredient exploration, promotion data, and health claim prediction packages for functional food development.
• Health Claim Prediction Package Predictive service using proprietary algorithms to predict health claims for functional foods based on metabolomic analysis.
• Bio-manufacturing Production Enhancement Support Service Support service for bio-manufacturing productivity enhancement using metabolomics for process optimization, including fermentation upcycling material development support.
• Analysis Kits and Consumables Sale of centrifugal filter units and miRNA analysis panels and primers for customer self-directed analysis, sold alongside service offerings.
• Food Metabolomics Application Application offering covering analysis of food components, metabolic changes during manufacturing, preparation and storage, functional component exploration, and dietary effect assessment for food science researchers and manufacturers.
• Regenerative Medicine Application Application offering supporting stem cell research, cell differentiation studies, and regenerative medicine applications for researchers in regenerative medicine and cell biology.

Quantifiable outcome

• Over 1,700 metabolites measurable in metabolome analysis service as of November 2025
• +3 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature9 records

Partnerships

Eight partnerships are on record, tiered core and supporting.

• AutoPhagyGO Inc.coreStrategic or Co-development Partner · 1 August 2023AutoPhagyGO Inc. and HMT entered a business partnership to advance autophagy research and social implementation. The partnership involves joint webinars and collaboration on autophagy activity evaluation services. In 2025, the collaboration achieved the world's first 'autophagy certification' for NMN using metabolomics evidence, demonstrating the application of HMT's metabolomics in substantiating health claims.
• AIREX Co., Ltd.coreStrategic or Co-development Partner · 1 May 2022AIREX and HMT entered a business partnership. Details of the collaboration are not fully specified in available sources but the partnership is listed as a formal business alliance alongside other strategic partnerships.
• MiRXES Pte Ltd.coreStrategic or Co-development Partner · 1 September 2021MiRXES and HMT entered a business partnership for miRNA analysis services. HMT provides commissioned miRNA analysis services using MiRXES's ID3EAL technology, and offers MiRXES miRNA analysis panels and primers for sale. The partnership expands HMT's service offerings beyond metabolomics into RNA analysis.
• Hirosaki University COIcoreStrategic or Co-development Partner · 1 May 2019HMT established a joint course 'Department of Metabolomics Innovation' at Hirosaki University Graduate School of Medicine in May 2019. The collaboration involves metabolome analysis of plasma and urine samples from participants in the Iwaki Health Promotion Project (cohort of over 2,000 participants with 10+ years of health data). Joint research has produced published methods for large-scale metabolome data correction, enabling reliable biomarker discovery in large-scale cohort studies. Research findings were published in Metabolites journal (Metabolomics Society).
• Keio University Institute for Advanced Biosciences (IAB)coreStrategic or Co-development PartnerHMT maintains an ongoing technical collaboration with Keio University's IAB. The CE-MS technology was originally developed in 2002 by Professor Tomoyoshi Soga of IAB (HMT co-founder). Professor Masaru Tomita, Director of IAB (HMT co-founder), is a recognized leader in computational biology and metabolomics. HMT develops its CE-MS method under joint research agreements, contributing to the advancement and popularization of metabolomics.
• Agilent Technologies, Inc.supportingTechnology or IntegrationHMT develops its CE-MS method under a joint research agreement with Agilent Technologies, Inc. Agilent provides the CE instrumentation component of HMT's CE-MS platform. This is a technology partnership supporting HMT's core analytical infrastructure.
• LKLS Co., Ltd. (Korea)supportingChannel Partner/ Reseller/ DistributorLKLS Co., Ltd. is an authorized distributor of HMT services in Korea. Located at #241, 100 Sinusil-ro, Hanam-si, Gyeonggi-do 12995, Korea. LKLS handles local sales, customer support, and sample logistics for Korean customers.
• GenDiscovery Biotechnology, Inc. (Taiwan)supportingChannel Partner/ Reseller/ DistributorGenDiscovery Biotechnology, Inc. is an authorized distributor of HMT services in Taiwan. Located at 25F-3, No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221, Taiwan. GenDiscovery handles local sales, customer support, and sample logistics for Taiwanese customers.

Scale indicators7 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• Metabolon: US-based leader in commissioned metabolomics and lipidomics analysis services for pharma and academia; directly overlaps with HMT's core untargeted/targeted metabolomics service model.
• Metware Biotechnology: China-based metabolomics and multi-omics contract analysis provider serving academic and industry researchers, comparable in service model and Asia-Pacific footprint.
• Sapient Bioanalytics: US metabolomics-driven discovery services company providing large-scale MS-based metabolite profiling for biomarker and drug development, closely aligned with HMT's platform.
• Nightingale Health: Finnish company offering NMR-based blood metabolomics for large cohorts and biomarker discovery, overlapping HMT's large-scale cohort metabolomics offering.
• Creative Proteomics: Contract lab offering metabolomics, proteomics and lipidomics analysis services, mirroring HMT's expanding multi-omics service portfolio.
• Biocrates Life Sciences: Austrian provider of targeted metabolomics and lipidomics kits and services using MS; competes directly in targeted metabolite quantification for biomarker research.

Others

• Agilent Technologies: Supplier of the CE and MS instrumentation underpinning HMT's platform and a technology partner; an enabling ecosystem participant rather than a direct competitor.

Broad incumbents

• Eurofins Scientific: Global bioanalytical testing and CRO network offering metabolomics and specialized lab services as part of a much broader portfolio overlapping HMT's contract analysis business.

Emerging players

• Chenomx: Provider of NMR metabolomics software and analysis services, comparable to HMT's combined measurement-plus-analytics-software approach.
• Owlstone Medical: UK company focused on breath-based metabolomics/VOC analysis and biomarker discovery, overlapping HMT's non-invasive metabolite measurement (skin gas) and biomarker services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/human-metabolome-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Human Metabolome Technologies